You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

Version: 2 ID: 3-15 sep 2014
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
Authors:
E. Basch, D.A. Loblaw, T.K. Oliver, C. Bennett, M. Carducci, R. Chen, J. Frame, K. Garrels, S. Hotte, M. Kattan, R. Nam, D. Raghavan, F. Saad, M.E. Taplin, C. Walker-Dilks, J. Williams, E. Winquist, T. Wooten, K. Virgo, CCO-ASCO Joint Castration Resistant Prostate Cancer Expert Panel Genitourinary Cancer Disease Site Group

Guideline Objective

To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC).

Patient Population

Men with metastatic castration-resistant prostate cancer.

Research Question(s)

In men with metastatic castration-resistant prostate cancer (mCRPC), which systemic therapies improve cancer- or patient-related outcomes?

pdf download Summary (PDF) (162.34 Ko)